Myriad Genetics, Inc. (0K3W.L)
USD 14.11
(0.53%)
USD 14.11
(0.53%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2022 | 1.19 Billion USD | -9.24% |
| 2021 | 1.32 Billion USD | -6.91% |
| 2020 | 1.41 Billion USD | -9.21% |
| 2019 | 1.56 Billion USD | 0.0% |
| 2018 | 1.56 Billion USD | 33.1% |
| 2017 | 1.17 Billion USD | -4.11% |
| 2016 | 1.22 Billion USD | 39.06% |
| 2015 | 880.5 Million USD | 14.92% |
| 2014 | 766.2 Million USD | -6.99% |
| 2013 | 823.81 Million USD | 2.49% |
| 2012 | 803.82 Million USD | 16.39% |
| 2011 | 690.63 Million USD | 13.07% |
| 2010 | 610.82 Million USD | 2.86% |
| 2009 | 593.84 Million USD | 27.32% |
| 2008 | 466.42 Million USD | -6.59% |
| 2007 | 499.34 Million USD | 34.21% |
| 2006 | 372.06 Million USD | 34.51% |
| 2005 | 276.6 Million USD | 74.01% |
| 2004 | 158.95 Million USD | -15.61% |
| 2003 | 188.35 Million USD | 3.03% |
| 2002 | 182.82 Million USD | 16.16% |
| 2001 | 157.39 Million USD | -8.57% |
| 2000 | 172.14 Million USD | 61.83% |
| 1999 | 106.37 Million USD | 98.46% |
| 1998 | 53.6 Million USD | -20.47% |
| 1997 | 67.4 Million USD | -11.43% |
| 1996 | 76.1 Million USD | -4.4% |
| 1995 | 79.6 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 Q1 | 1.16 Billion USD | -2.45% |
| 2023 Q3 | 1.14 Billion USD | -3.21% |
| 2023 Q2 | 1.18 Billion USD | 1.53% |
| 2022 Q4 | 1.19 Billion USD | -1.1% |
| 2022 Q1 | 1.25 Billion USD | -4.94% |
| 2022 Q3 | 1.21 Billion USD | 0.15% |
| 2022 Q2 | 1.21 Billion USD | -3.6% |
| 2022 FY | 1.19 Billion USD | -9.24% |
| 2021 FY | 1.32 Billion USD | -6.91% |
| 2021 Q2 | 1.36 Billion USD | 1.75% |
| 2021 Q3 | 1.33 Billion USD | -1.79% |
| 2021 Q4 | 1.32 Billion USD | -1.14% |
| 2021 Q1 | 1.33 Billion USD | -5.77% |
| 2020 Q1 | 1.44 Billion USD | -8.34% |
| 2020 Q3 | 1.44 Billion USD | 2.84% |
| 2020 Q2 | 1.4 Billion USD | -2.91% |
| 2020 FY | 1.41 Billion USD | -9.21% |
| 2020 Q4 | 1.41 Billion USD | -1.78% |
| 2019 Q4 | 1.57 Billion USD | -0.81% |
| 2019 Q2 | 1.56 Billion USD | 0.35% |
| 2019 FY | 1.56 Billion USD | 0.0% |
| 2019 Q1 | 1.55 Billion USD | 0.04% |
| 2019 Q3 | 1.59 Billion USD | 1.82% |
| 2018 FY | 1.56 Billion USD | 33.1% |
| 2018 Q1 | 1.21 Billion USD | -0.81% |
| 2018 Q2 | 1.17 Billion USD | -3.64% |
| 2018 Q3 | 1.57 Billion USD | 34.03% |
| 2018 Q4 | 1.55 Billion USD | -1.08% |
| 2017 Q4 | 1.22 Billion USD | 0.02% |
| 2017 FY | 1.17 Billion USD | -4.11% |
| 2017 Q3 | 1.22 Billion USD | 0.32% |
| 2017 Q2 | 1.22 Billion USD | -3.42% |
| 2017 Q1 | 1.26 Billion USD | -0.65% |
| 2016 Q2 | 880.5 Million USD | 1.42% |
| 2016 FY | 1.22 Billion USD | 39.06% |
| 2016 Q4 | 1.27 Billion USD | 0.41% |
| 2016 Q1 | 868.2 Million USD | -0.4% |
| 2016 Q3 | 1.27 Billion USD | 44.34% |
| 2015 FY | 880.5 Million USD | 14.92% |
| 2015 Q3 | 787 Million USD | 2.71% |
| 2015 Q4 | 871.7 Million USD | 10.76% |
| 2015 Q2 | 766.2 Million USD | -1.65% |
| 2015 Q1 | 779.04 Million USD | -0.36% |
| 2014 Q1 | 816.42 Million USD | 7.9% |
| 2014 Q4 | 781.85 Million USD | -3.36% |
| 2014 Q2 | 823.81 Million USD | 0.9% |
| 2014 FY | 766.2 Million USD | -6.99% |
| 2014 Q3 | 809 Million USD | -1.8% |
| 2013 Q1 | 729.02 Million USD | 1.57% |
| 2013 Q4 | 756.68 Million USD | -3.2% |
| 2013 Q3 | 781.65 Million USD | -2.76% |
| 2013 Q2 | 803.82 Million USD | 10.26% |
| 2013 FY | 823.81 Million USD | 2.49% |
| 2012 FY | 803.82 Million USD | 16.39% |
| 2012 Q4 | 717.74 Million USD | 2.09% |
| 2012 Q1 | 699.25 Million USD | 5.75% |
| 2012 Q2 | 690.63 Million USD | -1.23% |
| 2012 Q3 | 703.06 Million USD | 1.8% |
| 2011 Q2 | 610.82 Million USD | 9.61% |
| 2011 FY | 690.63 Million USD | 13.07% |
| 2011 Q4 | 661.25 Million USD | 6.7% |
| 2011 Q3 | 619.73 Million USD | 1.46% |
| 2011 Q1 | 557.28 Million USD | -6.12% |
| 2010 Q3 | 610.84 Million USD | 2.86% |
| 2010 Q4 | 593.6 Million USD | -2.82% |
| 2010 FY | 610.82 Million USD | 2.86% |
| 2010 Q1 | 589.56 Million USD | 9.17% |
| 2010 Q2 | 593.84 Million USD | 0.73% |
| 2009 Q1 | 620.43 Million USD | 8.17% |
| 2009 Q4 | 540.03 Million USD | 9.29% |
| 2009 Q2 | 466.42 Million USD | -24.82% |
| 2009 FY | 593.84 Million USD | 27.32% |
| 2009 Q3 | 494.12 Million USD | 5.94% |
| 2008 Q2 | 499.34 Million USD | 27.72% |
| 2008 Q4 | 573.56 Million USD | 7.97% |
| 2008 FY | 466.42 Million USD | -6.59% |
| 2008 Q1 | 390.95 Million USD | 1.72% |
| 2008 Q3 | 531.22 Million USD | 6.39% |
| 2007 Q4 | 384.35 Million USD | 2.94% |
| 2007 Q1 | 362.14 Million USD | 38.06% |
| 2007 FY | 499.34 Million USD | 34.21% |
| 2007 Q2 | 372.06 Million USD | 2.74% |
| 2007 Q3 | 373.37 Million USD | 0.35% |
| 2006 Q4 | 262.32 Million USD | -0.19% |
| 2006 FY | 372.06 Million USD | 34.51% |
| 2006 Q3 | 262.81 Million USD | -4.98% |
| 2006 Q1 | 278.29 Million USD | -2.43% |
| 2006 Q2 | 276.6 Million USD | -0.61% |
| 2005 Q3 | 150.03 Million USD | -5.61% |
| 2005 FY | 276.6 Million USD | 74.01% |
| 2005 Q1 | 160.58 Million USD | -6.29% |
| 2005 Q2 | 158.95 Million USD | -1.01% |
| 2005 Q4 | 285.22 Million USD | 90.11% |
| 2004 Q4 | 171.36 Million USD | -3.45% |
| 2004 Q2 | 188.35 Million USD | 26.99% |
| 2004 FY | 158.95 Million USD | -15.61% |
| 2004 Q3 | 177.47 Million USD | -5.78% |
| 2004 Q1 | 148.32 Million USD | -5.52% |
| 2003 Q1 | 182.91 Million USD | -7.2% |
| 2003 Q4 | 156.99 Million USD | -5.41% |
| 2003 Q3 | 165.97 Million USD | -9.21% |
| 2003 Q2 | 182.82 Million USD | -0.05% |
| 2003 FY | 188.35 Million USD | 3.03% |
| 2002 FY | 182.82 Million USD | 16.16% |
| 2002 Q2 | 157.39 Million USD | 2.42% |
| 2002 Q3 | 140.1 Million USD | -10.98% |
| 2002 Q1 | 153.66 Million USD | -3.31% |
| 2002 Q4 | 197.11 Million USD | 40.69% |
| 2001 Q3 | 161.24 Million USD | -6.33% |
| 2001 Q1 | 162.24 Million USD | 0.47% |
| 2001 Q2 | 172.14 Million USD | 6.1% |
| 2001 Q4 | 158.92 Million USD | -1.44% |
| 2001 FY | 157.39 Million USD | -8.57% |
| 2000 Q3 | 122.22 Million USD | 14.9% |
| 2000 Q4 | 161.48 Million USD | 32.12% |
| 2000 Q2 | 106.37 Million USD | 36.61% |
| 2000 Q1 | 77.86 Million USD | 5.37% |
| 2000 FY | 172.14 Million USD | 61.83% |
| 1999 Q2 | 53.6 Million USD | -4.63% |
| 1999 Q4 | 73.9 Million USD | 13.52% |
| 1999 Q3 | 65.1 Million USD | 21.46% |
| 1999 FY | 106.37 Million USD | 98.46% |
| 1999 Q1 | 56.2 Million USD | -4.91% |
| 1998 Q3 | 62.8 Million USD | -6.82% |
| 1998 FY | 53.6 Million USD | -20.47% |
| 1998 Q4 | 59.1 Million USD | -5.89% |
| 1998 Q1 | 69.5 Million USD | -4.27% |
| 1998 Q2 | 67.4 Million USD | -3.02% |
| 1997 Q3 | 74.6 Million USD | -1.97% |
| 1997 FY | 67.4 Million USD | -11.43% |
| 1997 Q4 | 72.6 Million USD | -2.68% |
| 1997 Q1 | 70.2 Million USD | -5.01% |
| 1997 Q2 | 76.1 Million USD | 8.4% |
| 1996 Q2 | 79.6 Million USD | -1.85% |
| 1996 Q1 | 81.1 Million USD | 3.05% |
| 1996 FY | 76.1 Million USD | -4.4% |
| 1996 Q4 | 73.9 Million USD | -4.77% |
| 1996 Q3 | 77.6 Million USD | -2.51% |
| 1995 Q4 | 78.7 Million USD | 0.0% |
| 1995 FY | 79.6 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Editas Medicine, Inc. | 499.15 Million USD | -140.147% |
| Dynavax Technologies Corporation | 997.09 Million USD | -20.219% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 14.924% |
| Perrigo Company plc | 10.8 Billion USD | 88.91% |
| Illumina, Inc. | 10.11 Billion USD | 88.145% |
| Thermo Fisher Scientific Inc. | 98.72 Billion USD | 98.786% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | -53.61% |
| Walgreens Boots Alliance, Inc. | 81.03 Billion USD | 98.521% |
| IQVIA Holdings Inc. | 26.68 Billion USD | 95.507% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -438.727% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 96.376% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -1724.783% |
| Waters Corporation | 4.62 Billion USD | 74.093% |
| Biogen Inc. | 26.84 Billion USD | 95.535% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -625.079% |
| Evolus, Inc. | 188.99 Million USD | -534.24% |
| Adicet Bio, Inc. | 207.29 Million USD | -478.258% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -852.529% |
| bluebird bio, Inc. | 619.16 Million USD | -93.601% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | -482.47% |
| FibroGen, Inc. | 423.52 Million USD | -183.027% |
| Agilent Technologies, Inc. | 10.76 Billion USD | 88.863% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -4139.825% |
| Homology Medicines, Inc. | 47.05 Million USD | -2447.336% |
| Geron Corporation | 394.07 Million USD | -204.18% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 68.701% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | -54.098% |
| Viking Therapeutics, Inc. | 368.49 Million USD | -225.301% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | 7.862% |
| Zoetis Inc. | 14.28 Billion USD | 91.609% |
| Abeona Therapeutics Inc. | 64 Million USD | -1772.91% |
| Mettler-Toledo International Inc. | 3.35 Billion USD | 64.277% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 82.479% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 94.726% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -2042.487% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 59.911% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -624.273% |
| Verastem, Inc. | 149.71 Million USD | -700.639% |
| Nektar Therapeutics | 398.03 Million USD | -201.156% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | -103.779% |
| Aclaris Therapeutics, Inc. | 197.4 Million USD | -507.229% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 63.282% |
| OPKO Health, Inc. | 2.01 Billion USD | 40.414% |
| Exelixis, Inc. | 2.94 Billion USD | 59.261% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 63.133% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | -92.867% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -676.431% |
| uniQure N.V. | 831.68 Million USD | -44.128% |
| Imunon, Inc. | 21.91 Million USD | -5369.004% |
| Blueprint Medicines Corporation | 1.04 Billion USD | -14.244% |
| Insmed Incorporated | 1.32 Billion USD | 9.861% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | 30.842% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | -27.913% |
| TG Therapeutics, Inc. | 329.58 Million USD | -263.698% |
| Incyte Corporation | 6.78 Billion USD | 82.326% |
| Emergent BioSolutions Inc. | 1.83 Billion USD | 34.672% |